Visum Pharmaceutical Co., Ltd reportedly raised close to RMB 100 million (USD 14.9 million) in a Series B+ financing round led by Zhejiang Hisoar Pharmaceutical Co., Ltd (SHE: 002099). The proceeds will be used to support the research and development (R&D) of high-end preparations and the construction of a GMP compliant workshop.
Company Profile
Founded in 2010, Visum Pharma is a comprehensive pharmaceutical enterprise integrating R&D, manufacturing, export, and marketing of high-end oral solid dosage forms. The company offers a range of capabilities in manufacturing sustained and controlled-release pellets, sustained and controlled-release matrix tablets, and insoluble drugs, among other technology platforms. This has enabled the successful development of more than 80 products.
Business Presence
Visum Pharmaceutical owns two manufacturing centers, two R&D centers, and one marketing center. The company markets five products in China and the US, and its exports of sustained and controlled-release preparations exceed 400 million tablets annually.-Fineline Info & Tech
